{
    "nct_id": "NCT04959903",
    "official_title": "A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Hematological Malignancies",
    "inclusion_criteria": "Group A (adults):\n\n1. Adult patients affected by:\n\n   * Acute leukemia (AML, ALL) defined as:\n\n     * Acute Myeloid Leukemia (AML):\n\n       * High risk AML in CR1; any adverse genetic abnormality, secondary or therapy related AML excluding good risk genetic abnormalities\n       * Chemo-refractory relapse (MRD+)\n       * ≥ CR2\n     * Acute Lymphoblastic Leukemia (ALL):\n\n       * Chemo-refractory relapse (MRD+)\n       * High risk ALL in CR1; Philadelphia (like) or any poor risk feature\n       * ≥ CR2\n     * Acute leukemia of ambiguous lineage:\n\n       * ≥ CR1 with a minimal residual disease (MRD) <5% (flow cytometry, molecular and/or cytogenetics accepted)\n   * Myelodysplastic Syndrome (MDS) with least one of the following:\n\n     * Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.\n     * Life-threatening cytopenia.\n     * Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.\n     * Therapy related disease or disease evolving from other malignant processes.\n2. Patient eligible for a T-depleted allogeneic HSCT\n3. Age ≥ 18y and clinical condition compatible with allogeneic stem cell transplantation\n4. Karnofsky index ≥ 70% prior to conditioning regimen\n5. Patients with normal organ function prior to conditioning regimen\n\nGroup B (pediatrics):\n\n1. Pediatric patients affected by acute leukemia defined as:\n\n   * Acute Myeloid Leukemia (AML):\n\n     * High risk AML in CR1; any adverse genetic abnormality, secondary or therapy related AML excluding good risk genetic abnormalities,\n     * Chemo-refractory relapse (MRD+)\n     * ≥ CR2\n   * Acute Lymphoblastic Leukemia (ALL):\n\n     * Chemo-refractory relapse (MRD+)\n     * High risk ALL in CR1; Philadelphia (like) or any poor risk feature\n     * ≥ CR2\n   * Acute leukemia of ambiguous lineage:\n\n     * ≥ CR1 with a minimal residual disease (MRD) <5% (flow cytometry, molecular and/or cytogenetics accepted)\n2. Patient eligible for a T-depleted allogeneic HSCT\n3. Age < 18y at the time of inclusion\n4. Absence of a matched sibling donor (MSD)\n5. Lansky ≥ 70% / Karnofsky performance status ≥ 70% prior to conditioning regimen\n6. Patients with normal organ function prior to conditioning regimen\nHealthy volunteers allowed",
    "exclusion_criteria": "Groups A and B:\n\n1. Use of an HLA matched Cord Blood (8/8 allele matched) or haploidentical donor\n2. Prior therapy with allogeneic stem cell transplantation\n3. Treatment with another cellular therapy within one month before inclusion",
    "miscellaneous_criteria": ""
}